Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 7/20 | 0.35 |
| ▸ | BCHE | P06276 | 2/20 | 0.32 |
| ▸ | BACE1 | P56817 | 2/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.32 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.32 |
| ▸ | CTSD | P07339 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 2/20 | 0.30 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
| ▸ | KMO | O15229 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13041491 | 0.89 | KDM4E (0.40) | KDM4EMAPT | |
| SCHEMBL13041555 | 0.89 | GRM2 (0.34) | GRM2BACE1S1PR1S1PR3 | |
| SCHEMBL13041511 | 0.88 | GLA (0.36) | GRM2KDM4EMAPTGLA | |
| SCHEMBL13041493 | 0.88 | GLA (0.32) | GLA | |
| SCHEMBL13986203 | 0.88 | GLA (0.30) | GLA | |
| SCHEMBL13078087 | 0.87 | GRM2 (0.32) | GRM2 | |
| SCHEMBL13041420 | 0.86 | GRM2 (0.36) | GRM2BCHEBACE1S1PR1BACE2 | |
| SCHEMBL13041519 | 0.83 | — | — | |
| SCHEMBL2762937 | 0.82 | HRH3 (0.41) | KDM4EMAPT | |
| SCHEMBL13041477 | 0.81 | PTPN11 (0.35) | GRM2KDM4ECYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8956999-B2 | Herbicides | SYNGENTA LIMITED (GB) | 2015-02-17 | — | — | US | disclosed |
| US-8956999-B2 | Herbicides | SYNGENTA LIMITED (GB) | 2015-02-17 | — | — | US | disclosed |
| EP-2173727-B1 | NOVEL HERBICIDES | SYNGENTA LTD (GB) | 2013-11-06 | — | — | EP | disclosed |
| US-20100279868-A1 | NOVEL HERBICIDES | SYNGENTA CROP PROTECTION, INC. (US) | 2010-11-04 | — | — | US | disclosed |
| WO-2009000533-A1 | NOVEL HERBICIDES | SYNGENTA LIMITED (GB) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100279868-A1 | NOVEL HERBICIDES | DDT, HPD, HSD17B1 | GRM2 156/4885BCHE 425/4885BACE1 2470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.